Navigation Links
Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
Date:5/6/2008

HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Jane Green, Kosan's Vice President, Corporate Communications, will present at the Leerink Swann Solid Tumors Roundtable Conference in New York at the Grand Hyatt Hotel on Friday, May 9, 2008 at 11:10 a.m. EDT. A live webcast of the presentation can be accessed through http://www.wsw.com/webcast/leerink15/kosn/.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentations will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
2. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
3. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
4. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
5. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
6. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
7. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
8. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
9. Kosan Announces February 28, 2008 Conference Call and Webcast
10. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
11. Kosan Announces Third Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novemb...nc. (Nasdaq: DCGN ) today announced the approval o...uptcy Court for the District of Delaware,(the "Ban...y petition for,relief under Chapter 11 of the Unit...t. , The orders issued by the Bankruptcy ...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia...Food & Drug Administration (SFDA) has approved...r its oral insulin project,(Nodlin), an innovative...pproval allows Biolaxy to initiate its first phase...er characteristic of high blood glucose and poor,m...
(Date:11/24/2009)... , , Primary efficacy endpoint has been me...t endometrial cancer, , QUEBEC CITY, Nov. 24 ...SDAQ: AEZS ; TSX: AEZ) (the "Company"), a global ...rapy and oncology, today announced positive effica...otoxic peptide conjugate, AEZS-108 (formerly AN-15...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-Fi...ARNA ) announced today that the company is sched...ealth Care Conference on December 1, 2009 at 11:30... New York Palace Hotel in New York City. Jack Lief...s scheduled to provide an overview of the company,...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
... , Ambion has developed a complete line...croRNAs (miRNAs). Recently, we introduced the mir...ng of the mir Vana miRNA Labeling Kit , an... tools for interrogating , miRNA function a...recursor , Molecules, Anti-miR miRNA Inhibi...
... Remove >90% of mammalian RNA from , ... Simple procedure takes less than 2 hou...cies , Seamless integration with ...rification Kit , Enables micro...erial RNA isolated from host cells , ...
..., Sonal Patel, and David Quilter , ... , Efficient and cost-effe... aRNA in a high throughput format , ... Rapid, reliable, and consisten...science researchers need an , efficient and...
Other Biology Technology:Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 2Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 3Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 4Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 5Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 6Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 7Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 8Bacterial RNA Isolation From Infected Eukaryotic Hosts 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 3Bacterial RNA Isolation From Infected Eukaryotic Hosts 4Bacterial RNA Isolation From Infected Eukaryotic Hosts 5Bacterial RNA Isolation From Infected Eukaryotic Hosts 6Automated RNA Amplification for Arrays 2Automated RNA Amplification for Arrays 3Automated RNA Amplification for Arrays 4Automated RNA Amplification for Arrays 5
(Date:11/24/2009)...pus Research Institute (LRI) today named 12 new gr... million, recognize innovative work across a broad... their creativity, novelty, and potential to drive..., and cure the complex disease of systemic lupus. ... lupus researchers across the nation and include i...
(Date:11/24/2009)...omic-level action of a remarkable class of ring-sh...ers with the Lawrence Berkeley National Laboratory...rystallography beamline at the Advanced Light Sour...in gene expression and replication, and are vital ...s infectious agents, such as the human papillomavi...
(Date:11/24/2009)...constitutes fish food is a matter of debate. A hig...h get almost 50 percent of their carbon from trees...n the terrestrial and aquatic ecosystems. , But ...ws this is not likely to be true. Algae provide a ...according to research published this week in the ...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Lymphoma Research Foundation announces recipients of CLL SLL Research Initiative grants 60249 1Lymphoma Research Foundation announces recipients of CLL SLL Research Initiative grants 60249 2Next generation microcapsules deliver chemicals on demand 10562 1UD start up company prepares to commercialize novel detector for medical military applications 10557 1UD start up company prepares to commercialize novel detector for medical military applications 10557 2UD start up company prepares to commercialize novel detector for medical military applications 10557 3UD start up company prepares to commercialize novel detector for medical military applications 10557 4
...lobe, hundreds of millions of acres of once-produc... a new report from researchers at Stanford Univers...his land was used to grow crops for conversion int...thout worsening the world food shortage or contrib...production for contributing to recent global food ...
...DC Engineered nanoscale materials (ENMs), which c...its for use in food packaging, raise new safety ev...ccording to a report released today by the Project...y Manufacturers Association (GMA). , The food-pa... share an interest in ensuring that any possible s...
...daylong event to help forge an agenda for maintain...tecting scientists from political meddling and cor...e NASA Goddard Institute for Space Studies, will s...ight Sides of Global Warming." Dr. Hansen is consi...nge and the need to take immediate action to curb ...
Other Biology News:Stanford study: Bioenergy potential of reviving abandoned agricultural land 2Stanford study: Bioenergy potential of reviving abandoned agricultural land 3Stanford study: Bioenergy potential of reviving abandoned agricultural land 4Use of nanomaterials in food packaging poses regulatory challenges 2NASA scientist James Hansen to speak at July 11 conference on 'Rejuvenating Public Sector Science' 2
...rade; SAPK/JNK (Thr183/Tyr185) Antibody Kit Kit I...dy, Catalog #9251, 200 ul SAPK/JNK (56G8) Rabbit m...Catalog #9253, (4 Western mini-blots) Anti-rabbit ...ti-biotin IgG, HRP-linked Antibody, Catalog #7075,...
Duck Anti-Phenytoin-BSA Antibody, Unconjugated from Good Biotech Corp
Rabbit Anti-GPCR TM7XN1 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-MEF2A, phospho (Thr312) Antibody, Unconjugated from Spring Bioscience
Biology Products: